Effects of Carnitine in Ischemic and Fatty Acid Supplemented Swine Hearts

A. JAMES LIEDTKE and STEPHEN H. NELLIS with the technical assistance of GARY COPENHAVER, Division of Cardiology, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania 17033

Abstract Free fatty acids (FFA) in excess FFA: albumin molar ratios have been determined to additionally compromise mechanical performance in ischemic hearts. Carnitine, an intracellular carrier of FFA and an agent which is lost to the heart during ischemia, has been postulated to in part restore function with its replacement. To test whether its benefits are also operative in a setting of excess FFA, these studies were performed. In the main protocol, four groups of perfused swine hearts (n = 45) were compared during 50 min of control flow (179.7 ml/min) and 40 min of global ischemia (106.1 ml/min). Initial base-line serum FFA:albumin molar ratios and carnitine levels in all groups were 1.3:1 and 8.5 nmol/ml, respectively. In two of these groups FFA:albumin ratios were increased to 5.9:1 with constant infusions of Intralipid. In two alternate groups (one with and one without extra FFA supplements) DL-carnitine was supplied, sufficient to increase serum levels nearly 200-fold. Ischemia per se in 14 hearts significantly decreased several parameters of global and regional mechanical function including left ventricular (LV) and mean aortic pressures, LV isovolumetric pressure development (max dp/dt), LV epicardial motion, and LV work, together with concomitant decreases in myocardial oxygen consumption. Elevated FFA in 12 hearts rendered similarly ischemic further decreased mechanical function (LV pressure: -20.8%, P < 0.05; mean aortic pressure -26.9%, P < 0.05; LV max dp/dt: -39%, P < 0.05; regional LV shortening: -51.1%, P < 0.05; and LV work: -50.3%, P < 0.05) as compared with nonsupplemented hearts. DL-Carnitine treatments in nine hearts, not supplemented with extra FFA were without apparent effect in improving overall hemo-

dynamic performance. However, DL-carnitine in 10 high FFA-ischemic hearts effected several improvements as compared with the untreated group: LV pressure was increased 25.6%, P < 0.025; mean aortic pressure: +43.5%, P < 0.05; LV max dp/dt: +41.5%, P < 0.05; regional LV shortening: +241.3%, P < 0.001; and LV work: +76.2%, P < 0.05 at comparable levels of myocardial oxygen consumption. In a separate protocol, the effects of stereospecificity were also studied by comparing L- with DL-carnitine in globally perfused, palmitate-supplemented hearts (five hearts in each treatment group). At similar conditions of flow and serum FFA, changes in mechanical function were comparable, except for a tendency to perform greater LV work at reduced flows in the L-carnitine-treated hearts. Thus, it was demonstrated that carnitine in ischemic hearts is capable of preserving mechanical function under conditions of excess FFA, presumably by modifying the toxic effects of FFA intermediates. The major therapeutic actions appeared to derive from the L-isomer of carnitine.

Introduction

Moderate levels of excess free fatty acids (FFA) have been shown previously to cause further deterioration in mechanical performance during global ischemia in working swine hearts (1). The mechanisms for this action are not yet known, but most likely they relate to the increased local concentrations of various fatty acid intermediates and their inhibitory effects on intracellular enzyme systems and membrane transport functions (2–7). The esters of long-chain acyl CoA represent one such group of these inhibitory FFA intermediates. These products are increased in ischemic myocardium and have been shown both to reduce the activity of mitochondrial adenine nucleotide trans-

1Abbreviations used in this paper: FFA, free fatty acids; LV, left ventricular; max dp/dt, isovolumetric pressure development.

Portions of these data were presented at the Joint Plenary Session of the Association of American Physicians, The American Society of Clinical Investigation, and the American Federation for Clinical Research, San Francisco, Calif., 30 April 1978.

Address reprints to Dr. Liedtke.

Received for publication 30 August 1978 and in revised form 15 March 1979.

locase and, in conjunction with decreases in cytosolic free 
carnitine (1, 8, 9), to impair fatty acid oxidation. It 
has been demonstrated further that restoring tissue 
levels of carnitine with treatments of L- or DL-carnitine 
tends to reverse these effects (4, 5, 10, 11). Such actions 
suggest a possible role for carnitine in the treatment 
of ischemic myocardium when FFA are elevated. 
Increases in plasma FFA occur frequently in patients 
with myocardial infarction, possibly as a result of 
enhanced sympathoadrenal activity and increased 
adipose tissue lypolysis, and have been postulated to 
precipitate life-threatening complications (12, 13). 
Tissue concentrations of long-chain acyl CoA are even 
further increased in FFA-treated ischemic hearts 
whereas tissue levels of acid-soluble carnitine are 
decreased further (1). Thus, these studies were undertaken 
in an effort to evaluate the effects of DL- 
and L-carnitine on the mechanical and metabolic functions of 
ischemic swine hearts in which controlled 
adjustments in coronary flow were regulated extracorporeally, 
and in which an excess of FFA was supplied.

METHODS

55 swine, weighing 36.3–74.1 kg (average 45.9 kg) were 
studied after anesthesia with pentobarbital (35 mg/kg) and the 
establishment of controlled positive pressure ventilation with 
100% O. In the main protocol an intact, working swine heart 
preparation (n = 45) was used to simultaneously collect 
information on mechanical function and metabolism. Specifics 
of this model, the instrumentation, types of measurements, 
and general format of data acquisition have been previously 
described (1). Basically, in this open-chest preparation, two 
extracorporeal circuits, supported by low-flow Sarns perfusion 
pumps (Sarns, Inc., Ann Arbor, Mich.), were constructed to 
separately perfuse the left and right coronary arteries. Normal 
flow in each circuit was determined by matching the mean 
 perfusion pressure with that of the peak systolic aortic pressure 
after correcting for line resistances. High-fidelity, manom-
eter-tipped pressure devices (Statham model P866, Statham 
Instruments, Inc., Oxnard, Calif.) were placed in the left 
ventricle and central aorta to measure pressures. A low 
mechanical impedence strain guage was fixed to the anterior 
epicardial surface of the heart near the apex to measure 
regional function (14). In separate studies, a second protocol 
was designed using a variation of the globally perfused swine 
heart preparation (n = 10), also previously described (15). 
Normal coronary flow in the separately cannulated left and 
right coronary arteries was determined by the above method. 
Cardiac output was adjusted to generate a left ventricular 
systolic pressure of ≈100 mm Hg, but not to exceed an end-
diastolic pressure of ≈20 mm Hg.

Mechanical data, together with the electrocardiogram, were 
displayed on an eight-channel Mark 200 Brush recorder and 
processed off-line with a Digital Equipment Corp. PDP 11/10 
(Maynard, Mass.). These data included heart rate, left ventricu-
lar and mean aortic pressures, and left ventricular (LV) 
isoeluvometric pressure development (max dp/dt). In the main 
protocol regional epicardial shortening, expressed in terms 
of natural strain(s), i.e., Δ lengths (L)/L, was also measured 
along with an index of regional work obtained throughout 
a computer-reconstructed cardiac cycle, defined as ∫ pressure 
work ds/dt·dt. In the second protocol global LV work was 

Effects of Carnitine in Ischemic Myocardium
FIGURE 1 Controlled variables in the four groups of swine hearts displayed as a function of the times of perfusion. Those groups of hearts without FFA supplements are shown in the upper two panels, hearts supplemented with excess FFA are shown in the bottom two panels. Open symbols refer to untreated groups; closed symbols refer to groups treated with DL-carnitine sufficient to increase serum concentrations ≈200-fold.

received DL-carnitine, and five only the L-isomer. Various parameters of hemodynamic performance were compared.

Paired and unpaired Student's t tests were used in all studies to estimate statistical significance with probability values defined as <5%. Variance of the data, where listed, appears as the standard error of the mean.

RESULTS

The independent variables regulated in the main protocol are shown as a function of the perfusion times in Fig. 1. Normal coronary flows in the control period for the four groups of swine hearts averaged 179.7 ml/min (127.1 ml/min in the left coronary circulation and 52.6 ml/min in the right coronary circulation). During ischemia, total coronary flow was reduced by 41% to 106.1 ml/min (79.2 ml/min and 26.9 ml/min in the left and right coronary arteries, respectively). There were no statistical differences in coronary flows among the groups. In nonsupplemented animals (low FFA, n = 14; low FFA-carn, n = 9), serum FFA averaged 0.32μM/ml with a FFA:albumin molar ratio of 1.3:1. Treatments with Intralipid in supplemented groups (high FFA, n = 12; high FFA-carn, n = 10) increased serum FFA approximately sixfold to an average FFA:albumin molar ratio of 5.9:1. There were no statistical differences in FFA levels between groups receiving no excess FFA or between groups given Intralipid at any time period of perfusion. Intrinsic serum carnitine concentrations in all animals averaged 8.5±0.9 nmol/ml. Treatments with constant infusions of DL-carnitine in low FFA-carn and high FFA-carn animals increased the serum carnitine concentration to an average value of 1,474 ±113 nmol/ml. This augmentation was achieved at a new steady-state level by 0 min perfusion time, and there were no statistical differences in values between groups.

Fig. 2 shows representative changes in mechanical and metabolic performance as a function of (a) restrictions in coronary flow and (b) treatments with DL-carnitine in hearts not supplemented with excess FFA. In untreated low FFA hearts at normal coronary flows (−30- to +20-min perfusion), LV pressure, regional LV shortening, and myocardial oxygen consumption remained either stable or improved. The same was true for mean aortic pressure (average value 88.0±0.6 mm Hg over this time period), LV max dp/dt (4,026±112 mm Hg/s), and regional LV work (119.3±9.7%). After restricting coronary flow, all of the above parameters fell significantly (P < 0.05 or greater, see Fig. 2), including mean

FIGURE 2 Mechanical and metabolic functions of non-FFA-supplemented hearts rendered globally ischemic between 20 and 30 min of perfusion. Treatments with DL-carnitine (closed circles) effected no significant changes in the general deterioration in performance observed to occur with ischemia except for a tendency to reduce oxygen consumption. Units for myocardial oxygen consumption are in millimoles per hour per gram dry.

A gift from Otsuka Pharmaceutical Factory, Naruto, Japan.
aortic pressure (−21.7%, P < 0.005), LV max dp/dt (−23.8%, P < 0.001), and regional work (−42.5%, P < 0.01). Thus, the mild-to-moderate restrictions in global perfusion were sufficient to produce early ischemic changes. Heart rate was unchanged during the course of perfusion. Treatments with DL-carnitine (low FFA-carn group) were without effect in changing any of the measurements of mechanical function or metabolism during either normal or ischemic flows with the exception of a slight tendency to reduce oxygen consumption.

Fig. 3 shows representative changes in mechanical and metabolic performance as a function of coronary flow and treatments with DL-carnitine in hearts supplemented with excess FFA. During myocardial ischemia, the presence of elevated FFA per se (high FFA group) caused significant declines in all measurements of global and regional mechanical function, including LV pressure (−20.8%, P < 0.05), mean aortic pressure (−26.9%, P < 0.05), LV max dp/dt (−39.5%, P < 0.05), regional shortening (−51.5%, P < 0.05), and regional LV work (−50.3%, P < 0.05). These trends were similar to those previously reported (1). Oxygen consumption at normal flows was significantly higher in this group after administration of FFA or as compared with low FFA hearts (P < 0.05 or greater), possibly because of the availability of excess substrate for utilization in aerobic metabolism. DL-carnitine in high FFA-carn hearts effected several changes in mechanical and metabolic functions. There was a maintenance of better performance over the course of perfusions with DL-carnitine treatments as demonstrated by the significant (P < 0.05 or greater) increases in LV pressure, LV max dp/dt, and regional LV shortening (Fig. 3), as well as mean aortic pressure (+43.5, P < 0.05) and regional work (+76.2%, P < 0.05), as compared with untreated high FFA hearts. These changes were observed at both normal and ischemic coronary flows but were most obvious and significant during the period of underperfusion. The early increases in oxygen consumption noted at normal flows in high FFA hearts were no longer present with DL-carnitine treatments.

**FIGURE 3** Mechanical and metabolic functions in FFA-supplemented hearts at control and ischemic conditions. Treatments with DL-carnitine (closed symbols) improved global and regional mechanical performance, particularly during ischemia, and decreased oxygen consumption during normal flows. Numbers above data points refer to statistical P values between treated and untreated hearts. Units as in Fig. 2, as shown.
Tissue data for the four groups are recorded in Table I. As previously reported in several studies (1, 8, 9), ischemia in mammalian hearts causes an increase in long-chain acyl CoA and carnitine and a decrease in acid-soluble (free and acetyl moieties) CoA and carnitine, as well as ATP and creatine phosphate. Addition of DL-carnitine in non-FFA-supplemented hearts effected no significant changes in CoA or carnitine stores, with the exception of a 39% increase ($P < 0.025$) in long-chain acyl carnitine as compared with untreated hearts. Excess FFA in ischemic hearts increased further the accumulations of long-chain acyl CoA and carnitine, decreased further the acid soluble fractions of CoA and carnitine, and led to a net loss of total carnitine stores. In this setting, treatments with DL-carnitine decreased the accumulations of long-chain acyl CoA ($P < 0.025$), restored the loss of acid soluble and total carnitine stores ($P < 0.025$ and $P < 0.005$, respectively), and increased the levels of long-chain acyl carnitine ($P < 0.05$). DL-carnitine treatments in either low or high FFA hearts did not increase the tissue stores of high energy phosphates.

It has previously been suggested that carnitine incorporation into cells is dependent upon its stereospecificity. The L-isomer of carnitine is readily concentrated by heart cells according to Michaelis-Menten kinetics (21). To test whether treatments with L-carnitine alone might further maintain mechanical function as noted with DL-carnitine, a second set of experiments were performed. The basic format of the studies was similar to that described above. 10 swine hearts, comparably treated with excess FFA (average serum values increased from 0.16±0.02 to 0.73±0.07 µM/ml, with FFA:albumin ratios increased from 0.83:1 to 3.46:1) were globally perfused at normal levels for 30 min, reduced over a 10-min period by −39.5%, and studied for an additional 30 min. In five hearts only L-carnitine was given (serum levels 4,656 nmol/ml); in five hearts DL-carnitine was given (serum levels 4,099 nmol/ml). Representative changes in mechanical performance are shown in Fig. 4. The effects of underperfusion beginning at 30-min perfusion time were obvious in both groups. Whereas there was a statistically significant trend toward improved function for left ventricular work during the early phases of myocardial ischemia in the group receiving L-carnitine only, the remainder of the changes were comparable. Myocardial oxygen consumption also declined similarly between 30 and 70 min of perfusion in both groups (average decline, −23.0%).

**DISCUSSION**

In a variety of clinical and experimental settings, FFA in increased concentrations have been shown to depress cardiac contractility at normal coronary flows (22, 23) and to precipitate ventricular dysrhythmias and further impair mechanical performance at ischemic coronary flows (1, 12, 13, 24–26). These actions appeared to result from the presence of “unbound” FFA in myocardial cells (13), which in turn are determined by increased molar ratios of FFA:albumin in the coronary perfusate (27). Threshold values above which these functional abnormalities occur are estimated to be in the range of 3–5:1 (1, 27, 28). Early attention centered on the actions of FFA to interfere with mitochondrial respiration. It was determined that excess FFA uncoupled electron transport from oxidative phosphorylation, inhibited oxidation per se, impaired ATP-inorganic phosphate exchange, and stimulated mitochondrial ATPase (2, 29–31). More recently attention has shifted to an evaluation of the effects of selected fatty acid intermediates on intracellular enzyme functions and
membrane transport. Of major interest has been the role and influence of long-chain acyl CoA. Several workers using subcellular preparations of heart, brain, and liver (7, 32, 33) have demonstrated that palmitoyl acyl CoA is capable of inhibiting a variety of enzyme systems including palmitoyl acyl CoA: carnitine palmitoyl acyl transferase (Kₐ 3 μM), long-chain acyl CoA synthetase (Kₐ 5 μM), and Na⁺, K⁺-ATPase (Kₐ 80 μM). As reported by Vignais (34) and Shug et al. (4) the enzyme most sensitive to the inhibitory effects of long-chain acyl CoA is adenine nucleotide translocase (Kₐ 0.1–0.3 μM). As can be seen, decreases in this translocase activity can occur at concentrations of the ester well within the critical micelle level. Moreover, because long-chain acyl CoA increases about twofold over aerobic values during restrictions in coronary flow (1, 8, 9), inhibition of this enzyme by the ester has been further speculated to be an early and important event in myocardial ischemia (4, 5, 9). Such interactions are reasoned to be even more pronounced in ischemic hearts supplemented with excess FFA because concentrations of long-chain acyl CoA are higher (1).

These studies were designed to evaluate the effects of carnitine in this setting of myocardial ischemia and excess FFA. Experiments were conducted with swine hearts, which were selected for their many close similarities to man in cardiovascular function, size, and perfusion distributions of the coronary circulation. Global rather than regional restrictions in coronary flow were chosen to improve the homogeneity of venous effluent and tissue for metabolic samplings. Mild rather than severe restrictions in coronary flow were chosen to experimentally approximate the conditions of a peri-infarction border zone where therapeutic modalities might have a better opportunity of effecting improvements as a result of greater preservation of cellular function. Exogenous rather than endogenous administration of FFA was necessitated in these studies. This may have introduced a bias toward greater toxic properties of the FFA because of the higher representation of polyunsaturates in the soybean oil emulsion (27). Against this, however, is the absence of reported harmful effects in long-term clinical trials where Intralipid has been used successfully in the treatment of malnutrition. Treatments with excess FFA in these studies were regulated to effect an increase in serum FFA:albumin ratios no greater than those which occur in the clinical setting.

Carnitine, an abundant normal constituent in myocardium, functions as a carrier of activated long-chain fatty acyl groups from the cytoplasm to the intramitochondrial sites of fatty acid oxidation. It also functions to transfer acetyl units between cytosol and mitochondrial matrix. This has been postulated in so doing to modulate the acyl transferase reaction and to serve as a buffer of matrix acetyl CoA by storing excess acetyl units in the cytoplasm (35). Shug et al. have shown that carnitine is lost from ischemic myocardium and that its replacement in mitochondrial preparations can reverse the inhibition of adenine nucleotide translocase by long-chain acyl CoA (5, 9, 36). In an intact canine model, carnitine was also shown to decrease epicardial ST segment deviation in ischemic tissue and to lessen the occurrence of ventricular fibrillation (10). In this study, carnitine did not appear to significantly improve mechanical dysfunction in nonsupplemented ischemic hearts but clearly benefited hemodynamic performance and motion in ischemic hearts.

Effects of Carnitine in Ischemic Myocardium 445
exposed to excess FFA. These improvements were unlike those effects previously reported for catechol-
amines in ischemic heart muscle where “improvements” were transient (<5 min) and associated with increased myocardial oxygen demands and ultimate further de-
struction of jeopardized tissue (37, 38). Tissue compar-
isons in the FFA-supplemented hearts revealed a significant decrease in long-chain acyl CoA in the carni-
tine-treated group together with significant increases of long-chain acid-soluble, and total carnitine. Total tissue stores for high-energy phosphates were not significantly changed with carnitine treatments. How-
ever, this most likely reflects the similarity in the restric-
tions in coronary flow between these groups and the untreated groups. The absence of changes in total tissue stores of ATP and creatine phosphate neither proves or disproves the “improvement in adenosine nucleotide translocase” effect of carnitine as proposed by Shug et al. (5, 9, 36). This would require detailed knowledge of intracellular distributions of products and the exact location of pools of critical adenosine intermediates. Such methods of measurement are cur-
tently unavailable for intact tissue.

Explanations regarding the therapeutic mechanisms of action for carnitine in a setting of increased FFA remain to be resolved but possible constructs include decreased myocardial oxygen consumption noted during normal flows in carnitine-treated, FFA-supplemented hearts could represent, in part, a decreased availability of fatty acid substrate for utilization. If this were so, the intracellular levels of any unbound fraction of FFA would also be decreased, thus lessening their toxic effects. The decreased tissue stores of long-chain acyl CoA observed in carnitine-treated hearts after 30 min of ischemia may further suggest a decrease in translocation of activated fatty acids into the mitochondria. Because 95% of the myocardial pool of CoA is located in the mito-
chondria, whereas carnitine is located primarily in the cytoplasm (39), the increase in long-chain acyl carnitine associated with a decrease in long-chain acyl CoA suggests a block at the level of acyl carnitine transport into mitochondria. Such an effect would have benefits by reducing the levels of the inhibitory acyl CoA ester in the mitochondrial matrix. Because D-carni-
tine is known to inhibit acyl carnitine transport (40), the presence of the D-isomer in DL-carnitine could account, in part, for the observed reduction in mito-
chondrial acyl CoA. However, in separate studies we were unable to demonstrate any broad-based statistical differences between the effects of DL- and L-carnitine on mechanical function. This suggested a therapeutic benefit from the L-isomer. Although tissue stores of ATP and creatine phosphate were no different in either group of FFA-supplemented hearts in the main protocol, a clear increase in the mechanical:metabolic efficiency ratio; i.e., selected functions of global or regional mechanical performance:myocardial oxygen consumption, was noted with DL-carnitine treatment. Finally, it has been reported that palmitylcarnitine is also capable of inhibiting certain enzymes, including Na+, K+-ATPase. Because this fraction increased with FFA supplements and further increased with DL-carnitine treatments, the potential for impairing performance of this enzyme was possible. However, the reported Kᵢ for this intermediate is 44–48 μM and considerably outside the concentration levels observed in this study. Interference with the activity of this enzyme was therefore not considered a major influence in these results.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the assistance of Larry Whitsett and Jane Fuhrman in the performance of these studies and the secretarial assistance of Audrey Weikel, Brenda Brubaker, and Pandora Reese.

This work was supported in part by grant HL-21209, The South Central Pennsylvania Chapter of the American Heart Association, and the Sam Ostrow Cardiology Research Fund.

REFERENCES


